LataMed AI Corp. (OTC: LMED), a digital health and artificial intelligence technology company focused on telehealth infrastructure and healthcare analytics for emerging markets, announced it expects to formally submit a corporate action request to FINRA today for a proposed five-for-one (5-for-1) forward stock split. The split would apply proportionally to all issued and outstanding shares of common stock and preferred stock, including Series C Voting Preferred Stock, and would be accompanied by proportional increases in authorized common and preferred stock.
The company stated that the proposed forward stock split is intended to support long-term operational scalability, strategic flexibility, capitalization planning, and future growth initiatives as it continues advancing telehealth infrastructure deployment, healthcare analytics integration, regulatory progression, and commercialization throughout Latin America and other targeted emerging markets. Management emphasized that the corporate action does not involve debt restructuring, recapitalization, or a reduction in shareholder ownership percentages. No fractional shares are expected to be issued, as any fractional interests would be rounded up to the nearest whole share.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., said: 'As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives as we continue building our healthcare technology platform.'
The company recently announced the commencement of initial operational activities for its telehealth platform in Venezuela, following regulatory authorization from the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS). This forward stock split is part of LataMed's broader effort to align its capital structure with its transition into digital healthcare infrastructure and AI-driven telehealth operations.
The proposed stock split remains subject to FINRA review and approval, completion of applicable regulatory processing, and final corporate implementation procedures. No assurance can be provided regarding the timing or ultimate effectiveness of the corporate action. For more information, visit https://latamed.ai or review the company's filings with the SEC at www.sec.gov.
LataMed AI Corp. is a development-stage digital health and AI technology company focused on scalable telehealth and healthcare analytics platforms for emerging markets, with an initial emphasis on Latin America. The company has not generated revenues from its current business operations and is advancing a technology-enabled healthcare ecosystem for remote patient engagement, provider coordination, and digital healthcare delivery.
